Published in Hepatitis Weekly, November 25th, 2002
The objective of the study, called AEGIS (Anti-fibrotic Efficacy Gamma Interferon Study), is to evaluate the safety and antifibrotic activity of Actimmune in HCV patients who have failed standard antiviral therapy.
Henry Hsu, MD, InterMune, said, "Preclinical and preliminary clinical data suggest that interferon gamma may prevent or reverse the development of cirrhosis. Based on these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.